Revenue growth decelerated sharply to 3% from prior quarters' 16-19% annual growth, and the company is burning ~$11M/quarter with only $39.5M cash. Monitor Q2 2026 revenue (~$20.0M guided) and whether the OviTex LTR launch and European expansion can re-accelerate growth; the cash runway is limited without a capital raise.
Price Chart
Executive Summary
TELA Bio reported Q1 2026 revenue of $19.1M (+3% YoY), slightly above the $19.0M preliminary estimate, and a net loss of $12.3M ($-0.21 per share), which widened from $11.3M in Q1 2025. The company reiterated full-year 2026 revenue guidance of at least 8% growth and guided Q2 2026 revenue to ~$20.0M, but the 3% quarterly growth rate is a deceleration from prior periods and operating losses remain elevated, making this a mixed result.
Key Financial Metrics
Key Facts
- Q1 2026 revenue of $19.1M, up 3% YoY from $18.5M, in line with the $19.0M preliminary estimate
- Net loss widened to $12.3M ($-0.21 per share) from $11.3M ($-0.25 per share) in Q1 2025
- Gross margin declined to 65.7% from 67.6% YoY due to higher excess/obsolete inventory charges
- Operating expenses flat at $23.0M; loss from operations unchanged at $10.5M
- Cash and cash equivalents fell to $39.5M from $50.8M at year-end 2025, a burn of ~$11.3M
- Full-year 2026 revenue guidance reiterated at 'at least 8% growth' over 2025; Q2 2026 revenue guided to ~$20.0M
- European revenue grew 41% YoY; U.S. commercial launch of OviTex LTR initiated April 1, 2026
- Board refreshment plan announced in April 2026 with several director resignations and new appointments effective June 9, 2026
Financial Impact
Revenue $19.1M (+3% YoY), net loss $12.3M, cash burn $11.3M in Q1
Risk Factors
- Cash burn rate of ~$11M/quarter with $39.5M on hand implies less than 4 quarters of runway
- Revenue growth deceleration to 3% from prior double-digit rates signals potential market saturation or competitive pressure
- Gross margin compression from 67.6% to 65.7% due to inventory obsolescence charges
- Board refreshment with multiple director departures creates near-term governance uncertainty
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-059393 |
| Document: tm2614218d1_8k.htm | 0001104659-26-059393 |
| Document: tm2614218d1_ex99-2.htm | 0001104659-26-059393 |
| Document: 0001104659-26-059393-index-headers.html | 0001104659-26-059393 |
| Document: 0001104659-26-059393-index.html | 0001104659-26-059393 |
| Document: 0001104659-26-059393.txt | 0001104659-26-059393 |
| 8-K Data (Synthetic) | 0001104659-26-059393 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | 8-K | $0.7380 $1.24 | ▲ +68.02% | ▲ +68.21% | $1.19 (+61.25%) |
Aug 10, 2026 7w ago | 8-K | $0.7900 $0.9113 | ▼ −15.35% | ▼ −16.41% | $1.19 (−50.63%) |
Jun 11, 2026 16w ago | 3 | $0.8600 $0.8470 | ▼ −1.51% | ▼ −3.29% | $1.19 (+38.37%) |
Jun 11, 2026 16w ago | 3 | $0.8600 $0.8470 | ▼ −1.51% | ▼ −3.29% | $1.19 (+38.37%) |
Jun 11, 2026 16w ago | 3 | $0.8600 $0.8470 | ▼ −1.51% | ▼ −3.29% | $1.19 (+38.37%) |
Jun 11, 2026 16w ago | 3 | $0.8600 $0.8470 | ▼ −1.51% | ▼ −3.29% | $1.19 (+38.37%) |
May 12, 2026 20w ago | 8-K | $0.9600 $0.9120 | ▼ −5.00% | ▼ −4.39% | $1.19 (+23.96%) |
May 12, 2026 20w ago | Press Release | $0.9600 $0.9120 | ▲ +5.00% | ▲ +4.39% | $1.19 (−23.96%) |
Apr 30, 2026 22w ago | 8-K | $0.9890 $0.9000 | ▼ −9.00% | ▼ −14.28% | $1.19 (+20.32%) |
Apr 21, 2026 23w ago | Press Release | $0.6250 $0.8600 | ▲ +37.60% | ▲ +34.43% | $1.19 (+90.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access